Department of Renal Medicine, Royal Infirmary of Edinburgh, National Health Service Lothian, UK (I.M.M., T.E.F.).
University/British Heart Foundation Center of Research Excellence, Center for Cardiovascular Science, Queen's Medical Research Institute (I.M.M., E.J.T., T.E.F., J.W.D., D.J.W.), University of Edinburgh, UK.
Circulation. 2022 Feb 8;145(6):416-423. doi: 10.1161/CIRCULATIONAHA.121.056015. Epub 2022 Feb 7.
Acetaminophen is widely used as first-line therapy for chronic pain because of its perceived safety and the assumption that, unlike nonsteroidal anti-inflammatory drugs, it has little or no effect on blood pressure (BP). Although observational studies suggest that acetaminophen may increase BP, clinical trials are lacking. We, therefore, studied the effects of regular acetaminophen dosing on BP in individuals with hypertension.
In this double-blind, placebo-controlled, crossover study, 110 individuals were randomized to receive 1 g acetaminophen 4× daily or matched placebo for 2 weeks followed by a 2-week washout period before crossing over to the alternate treatment. At the beginning and end of each treatment period, 24-hour ambulatory BPs were measured. The primary outcome was a comparison of the change in mean daytime systolic BP from baseline to end of treatment between the placebo and acetaminophen arms.
One-hundred three patients completed both arms of the study. Regular acetaminophen, compared with placebo, resulted in a significant increase in mean daytime systolic BP (132.8±10.5 to 136.5±10.1 mm Hg [acetaminophen] vs 133.9±10.3 to 132.5±9.9 mm Hg [placebo]; <0.0001) with a placebo-corrected increase of 4.7 mm Hg (95% CI, 2.9-6.6) and mean daytime diastolic BP (81.2±8.0 to 82.1±7.8 mm Hg [acetaminophen] vs 81.7±7.9 to 80.9±7.8 mm Hg [placebo]; =0.005) with a placebo-corrected increase of 1.6 mm Hg (95% CI, 0.5-2.7). Similar findings were seen for 24-hour ambulatory and clinic BPs.
Regular daily intake of 4 g acetaminophen increases systolic BP in individuals with hypertension by ≈5 mm Hg when compared with placebo; this increases cardiovascular risk and calls into question the safety of regular acetaminophen use in this situation. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01997112. URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2013-003204-40.
由于对乙酰氨基酚的安全性的认知,以及假设它对血压(BP)几乎没有影响或没有影响,与非甾体抗炎药不同,它被广泛用作慢性疼痛的一线治疗药物。尽管观察性研究表明对乙酰氨基酚可能会升高血压,但临床试验却缺乏。因此,我们研究了常规剂量对乙酰氨基酚对高血压患者血压的影响。
在这项双盲、安慰剂对照、交叉研究中,110 名参与者被随机分配接受每天 4 次 1 克对乙酰氨基酚或匹配的安慰剂,持续 2 周,然后在交叉到另一种治疗前进行 2 周的洗脱期。在每个治疗期的开始和结束时,测量 24 小时动态血压。主要结局是比较安慰剂和对乙酰氨基酚组之间从基线到治疗结束时平均日间收缩压的变化。
103 名患者完成了研究的两个阶段。与安慰剂相比,常规对乙酰氨基酚治疗导致平均日间收缩压显著升高(132.8±10.5 至 136.5±10.1 mmHg[对乙酰氨基酚] vs 133.9±10.3 至 132.5±9.9 mmHg[安慰剂];<0.0001),安慰剂校正后增加 4.7 mmHg(95%CI,2.9-6.6),平均日间舒张压(81.2±8.0 至 82.1±7.8 mmHg[对乙酰氨基酚] vs 81.7±7.9 至 80.9±7.8 mmHg[安慰剂];=0.005),安慰剂校正后增加 1.6 mmHg(95%CI,0.5-2.7)。24 小时动态和诊室血压也有类似发现。
与安慰剂相比,每日摄入 4 克对乙酰氨基酚可使高血压患者的收缩压升高约 5 mmHg;这增加了心血管风险,并质疑在这种情况下常规使用对乙酰氨基酚的安全性。
网址:https://www.clinicaltrials.gov;唯一标识符:NCT01997112. 网址:https://www.clinicaltrialsregister.eu;唯一标识符:2013-003204-40.